Journal Watch

  • Home HD: Hospitalizations and Technique Survival

    In a Swedish registry study, patients initiating PD (n=456), home HD (n=152), and in-center HD (IHD; n=608) were matched by age, sex, comorbidity, and start date. Patients using home HD had significantly lower hospital admissions and days than those doing PD or IHD (1.7, 12 days vs. 2.8, 20 days and 2.2, 14 days respectively). Home HD patients also had significantly fewer admissions for cardiovascular diagnoses or infectious disease, as well as significantly longer technique survival.

    Read the abstract » | (added 2020-01-09)

  • PD—Controlling Volume to Reach Normal Hydration Protects the Heart

    Reanalysis of data from a multicenter, prospective, randomized controlled trial looked at fluid control in PD in 151 patients followed for a year. While most (120) reached normal hydration levels as measured by bioimpedance analysis, those who did not had significantly higher left atrial diameter—and a lower left ventricular ejection fraction at the end of the study.

    Read the abstract » | (added 2019-12-10)

  • Simultaneous Hernia Repair and PD Catheter Placement

    Taking care of two surgeries at once saves a procedure, recovery time, and costs. Among 123 patients who had catheters placed at a single center over a 4-year period, 23 (19%) had hernias. Across the 23, 27 procedures were done combining hernia repair with PD catheter placement. None of the hernias recurred, and there were no early surgical site infections. Five of the patients developed new hernias at other sites, but after a median of about 3 years, 96% of the catheters were still working.

    Read the abstract » | (added 2019-12-10)

  • European Patients Live Longer with Extended HD Treatments

    Compared to standard in-center HD, patients from eight European countries who dialyzed for 6+ hours thrice weekly lived longer. Of 142,460 patients, 1,338 did extended HD. Compared to in-center HD (13.5/100 person-years), crude mortality for extended HD (6.0/100 person-years) was significantly better. Overall, those treated with extended treatments were 73% more likely to have survived.

    Read the abstract » | (added 2019-12-10)

  • Higher Serum Phosphorus Predicts More Residual Function Loss—in Men Only

    A retrospective analysis of 1,245 CAPD patients followed for up to 11 years divided participants into tertiles based on their baseline serum phosphorus levels. One third of patients lost residual renal function (RRF) during the study, and those with the highest baseline phosphorus levels had a 51% higher risk of RRF loss than those in tertiles 1 and 2 combined. The risk of RRF loss was significantly higher for men.

    Read the abstract » | (added 2019-12-10)

  • In-center Nocturnal HD: Fewer Complications than PD in Patients with PKD

    An analysis that matched PDK patients who did conventional HD (26) or PD (26) to in-center nocturnal HD (NHD; 13) found no significant difference in mortality—but after a median follow up of 5.5 years, NHD had significantly fewer complications than PD—and higher serum albumin levels as well.

    Read the abstract » | (added 2019-12-10)

  • Transplant Survival Better After PD Than Standard In-center HD

    Is there an advantage to PD over standard in-center HD for transplant graft survival? YES, suggests a 15-year retrospective study of 2,277 transplant recipients. Those who did PD prior to transplant were 34.5% more likely to survive, and had less frequent rejection. Living donor kidneys did best among patients who received transplants before starting dialysis—or did PD.

    Read the abstract » | (added 2019-11-16)

  • PD vs. Standard In-center HD for Quality of Life

    A 24-month observational study compared 45 standard HD and 30 PD patients, and assessed their quality of life, cognitive function, and depression at study start and every 12 months. Over the 24 months, PD patients had significant improvement in physical and social well-being—while HD patients stayed the same. Cognitive function held steady in PD patients—but declined in HD patients. Depression increased among those on standard HD—but not those on PD.

    Read the abstract » | (added 2019-11-16)

  • Tablo HD Machine Safe and Effective at Home and In-center

    Safety and efficacy human trials of the easy-to-use Tablo were conducted with 28 participants who received 4 treatments per week in-center and then at home for a total of 21 weeks. Home adherence (99%) was slightly better than in-center (96%), with average prescribed—and delivered—treatments of 3.4 hours, and an average weekly standard Kt/Vurea of 2.8 in both settings. Adverse events were not related to the Tablo, and alarm resolution time was 8 seconds in-center and 5 seconds at home.

    Read the abstract » | (added 2019-11-16)

  • A Post-op Surgical Girdle for Pain and Catheter Tunnel Infections in Urgent Start PD

    Urgent start PD can be associated with pain and tunnel infections. In a study of 85 consecutive PD catheter placements, a surgical girdle was used from days 1-3 while patients were supine. Among the 23 patients who completed pain surveys, the girdle helped significantly. Tunnel infections were reduced as well.

    Read the abstract » | (added 2019-11-16)